Sulfonylureas & glinides × cardiovascular events

SynthesisThe Cochrane database of systematic reviews2016

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Bianca Hemmingsen et al.PubMed ↗Full text ↗Publisher ↗

  • Nateglinideno clear effectNo clear effect on MI, non-fatal stroke and HF.Nothing cleared the noise.

What the trial testedas reported · 10,018 people · 2016

Range includes no effect

No clear effect on MI, non-fatal stroke and HF

−15%−36% to +14%

nateglinide vs placebo

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.64–1.14

Who was studied, and how

10,018people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

nateglinide
placebo

No clear effect on MI, non-fatal stroke and HF−15%

randomised

the abstract, start to end

(1.8%) versus 100/4661 (2.1%) - (HR 0.85; 95% CI 0.64 to 1.14; P =

← favours treatmentfavours comparator →
could be chance
MI, non-fatal stroke and HFnateglinide vs placebo
HR 0.850.64–1.14
Sulfonylureas & glinidesCardiovascular events

Sulfonylureas & glinides × cardiovascular eventshelps?replicated

unlikelylikely
0.96not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

15 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27749986